Avoro Capital Advisors LLCAvoro Capital Advisors LLC

Institutional investor · Portfolio as of Q3 2019

SEC EDGAR SourceSEC Filings

Top Holdings33 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
MRTXMRTXDelisted

MIRATI THERAPEUTICS INC

3.8M$292.2M12.2%
3 qtrssince 2019-Q1
Decreased
0
IMMUIMMUDelisted

IMMUNOMEDICS INC

21M$278.5M11.6%
3 qtrssince 2019-Q1
Unchanged
0

IOVANCE BIOTHERAPEUTICS INC

10.6M$192.9M8.0%$9.82+83.21%
3 qtrssince 2019-Q1
Decreased
0
ASNDASND
ADR

ASCENDIS PHARMA A/S

2M$189.8M7.9%$117.47-18.12%
3 qtrssince 2019-Q1
Unchanged
0

BIOMARIN PHARMACEUTICAL INC

2.4M$164.3M6.9%$84.82-19.46%
3 qtrssince 2019-Q1
Increased
69
AMRNAMRN
ADR

Amarin Corporation plc

8.5M$129.2M5.4%

AVI BIOPHARMA INC

1.7M$126.4M5.3%$115.87-35.27%
3 qtrssince 2019-Q1
Increased
70
HZNPHZNPDelisted

HORIZON THERAPEUTICS PLC

4M$108.9M4.5%
2 qtrssince 2019-Q2
Unchanged
0
ARGXARGX
ADR

ARGENX SE - ADR

835,000$95.2M4.0%$124.84-9.24%
3 qtrssince 2019-Q1
Decreased
0
FOLDFOLDDelisted

AMICUS THERAPEUTICS INC

11.1M$89M3.7%$13.00-37.93%
3 qtrssince 2019-Q1
Increased
62
MYOKMYOKDelisted

MYOKARDIA INC

1.6M$81M3.4%
3 qtrssince 2019-Q1
Increased
63
ZGNXZGNXDelisted

ZOGENIX INC

1.9M$75.1M3.1%
3 qtrssince 2019-Q1
Decreased
0
ATNXATNXDelisted

ATHENEX INC

5.9M$71.7M3.0%
2 qtrssince 2019-Q2
Increased
64
TCDAQTCDAQDelisted

TRICIDA INC

2.2M$67.9M2.8%
3 qtrssince 2019-Q1
Unchanged
0

PACIRA BIOSCIENCES INC

1.6M$60.9M2.5%$39.52-41.79%
3 qtrssince 2019-Q1
Increased
83

Karyopharm Therapeutics Inc.

6.1M$58.2M2.4%
GBTGBTDelisted

GLOBAL BLOOD THERAPEUTICS INC

1M$48.5M2.0%
3 qtrssince 2019-Q1
Increased
54

ACADIA Pharmaceuticals Inc.

887,500$31.9M1.3%$26.85+36.98%
3 qtrssince 2019-Q1
Decreased
0
BDSIBDSIDelisted

BIODELIVERY SCIENCES INTL INC

7.4M$31.3M1.3%
3 qtrssince 2019-Q1
Unchanged
0

MADRIGAL PHARMACEUTICALS INC

360,000$31M1.3%$122.42-30.46%
3 qtrssince 2019-Q1
Unchanged
0
$2.4B
AUM
33
Positions
Q3 2019
Filing
Rating · 1.5
Quarterly Portfolio Change
+25%Q2'19$2.9B-17%Q3'19$2.4B
Activity profile
$ moved · Q3'19
New11%Increased37%Decreased35%Exited16%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.6 quarters
<1Q6%1-4Q82%1-2Y0%2Y+12%

Avoro Capital Advisors LLC manages $2.4B across 33 positions as of Q3 2019. Top holdings: MRTX (12.2%), IMMU (11.6%), IOVA (8.0%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.

Q3 2019 Summary

Added 3 new positions, exited 3, increased 9, trimmed 7. Top move: PCRX (INCREASED, conviction 83). Portfolio: $2.4B across 33 positions.

Top holdings by portfolio weight

Total AUM$2B
MRTX12.19%
IMMU11.62%
IOVA8.05%
ASND7.92%
BMRN6.85%
AMRN5.39%
SRPT5.27%
HZNP4.54%
ARGX3.97%
FOLD3.71%
Other3.38%

Portfolio allocation by GICS sector

Sectors2
Healthcare53.16%
Unknown46.84%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension quality assessment
Below Average(1.5 / 5.0)
Track RecordNo data
Conviction47
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
4Q
OCULOCULOCULAR THERAPEUTIX INC
Q3 2025 Q2 2026+5.1M shares+$54.5M
3Q
UTHRUTHRUNITED THERAPEUTICS CORP
Q4 2025 Q2 2026+755,555 shares+$657.3M
2Q
ARWRARWRARROWHEAD PHARMACEUTICALS IN
Q1 2026 Q2 2026+730,555 shares+$220.2M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used